Dermira, Redwood City, California 94061, USA.
J Invest Dermatol. 2012 Mar;132(3 Pt 2):1033-6. doi: 10.1038/jid.2011.368.
Over the past 25 years both the quality and quantity of pharmaceutical and biopharmaceutical research has changed. Formerly rigidly separated research efforts in academic institutions and the biopharmaceutical industry have become increasingly transparent to one another. Industry has in some cases scaled down its internal research efforts, while enhancing its outreach to basic research in academic institutions. In parallel, research at academic institutions has-in some cases-added a focus on application of discoveries to patient needs. This porosity between industry and academia has created opportunities for more rapid translation of basic discoveries to patient needs. Additionally, both physicians and fundamental scientists have broadened their career opportunities, and movement between industry and academia-almost unheard of two decades ago-now occurs regularly. At the same time, numerous examples exist of how these translational efforts have benefited not only patients but also investigators and academic institutions as well. Despite many potential advantages of closer interactions between industry and academia, other issues, such as conflicts of interest (both real and perceived), continue to pose challenges.
在过去的 25 年中，药物和生物制药研究的质量和数量都发生了变化。以前，学术界和生物制药行业的研究工作是严格分开的，现在它们之间的透明度越来越高。在某些情况下，行业已经减少了内部研究工作，同时加强了与学术机构基础研究的联系。与此同时，学术机构的研究——在某些情况下——增加了将发现应用于患者需求的重点。这种行业和学术界之间的渗透性为将基础发现更快地转化为患者需求创造了机会。此外，医生和基础科学家都扩大了他们的职业机会，而且行业和学术界之间的人员流动——在二十年前几乎闻所未闻——现在经常发生。与此同时，有许多例子表明，这些转化工作不仅使患者受益，也使研究人员和学术机构受益。尽管行业和学术界之间更紧密的互动有许多潜在的优势，但其他问题，如利益冲突（真实的和感知到的），仍然构成挑战。
